Resverlogix: The Future of Drug Development
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-bas …
Developing safe, epigenetic therapeutics for people suffering from chronic illnesses
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.
For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.
Latest Articles
Hot Companies
You might also like
Volta Metals: Powering the Future with Ontario’s Critical Minerals
As global demand for critical minerals surges, Volta Metals is strategically positioned in Northwestern Ontario, exploring lithium and rare metals in proximity to infrastructure and clean energy sources.
.png)
.png)
